Many Hh-dependent cancers are driven by activating mutations that occur downstream of Smo, affecting the transcription factors known as glioma-associated oncogenes (Gli1–3), which mediate the transcriptional effects of Hh pathway activation [18]. This evidence concerns the gene GLI1 and cancer.